In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouringEGFR mutation (EGFRm).
Survival outcomes of women diagnosed with breast cancer during pregnancy are similar to that of non-pregnant women, according to a presentation at ESMO Asia 2017. However, it is important to identify the dos and don’ts when diagnosing and treating breast cancer in this population.
Treatment with the PD-L1* inhibitor durvalumab after chemoradiotherapy significantly prolongs progression-free survival (PFS) by 11 months in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC), with similar benefits in an Asian subset, according to the PACIFIC** study presented at ESMO Asia 2017 in Singapore.
A week-on week-off (WOWO) gemcitabine/nab-paclitaxel (gem/nab-P) regimen appears to be as effective but potentially less toxic than standard gem/nab-P for advanced pancreatic cancer, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2017 Congress.
Consistent with literature findings, palbociclib is generally well-tolerated and effective in controlling the disease of Asian patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), reports a new study from Hong Kong presented at the recently concluded European Society for Medical Oncology (ESMO) Asia 2017 Congress.
Regorafenib appears to have promising efficacy as a third- or fourth-line treatment for patients with metastatic colorectal cancer (mCRC), according to a new study from Macau presented at the recently concluded European Society for Medical Oncology Asia 2017 Congress (ESMO Asia 2017).
There is no significant difference in progression-free survival (PFS) or endoscopic biopsy complete response (CR) rate between patients with localized gastro-oesophageal carcinoma (GOC) undergoing radical chemoradiation therapy (CRT) with carboplatin and those with cisplatin, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2017 Congress.
Strength training interventions for cancer patients are safe and well tolerated, having the potential to increase muscle mass and strength and subsequently improve physical function and quality of life, according to a team of Latvia-based investigators.